Neratinib (HKI-272)

For research use only. Not for use in humans.

目录号：S2150 中文名称：来那替尼

CAS No. 698387-09-6

Neratinib (HKI-272)是一种高度选择性的HER2和EGFR抑制剂，在无细胞试验中IC50分别为59 nM 和 92 nM；微弱抑制KDR和Src，对Akt，CDK1/2/4，IKK-2，MK-2，PDK1，c-Raf和c-Met没有显著的抑制作用。Phase 3。

规格

价格

库存

购买数量

5mg	RMB 1227.96	现货
25mg	RMB 3863.92	现货
100mg	RMB 7933.43	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Neratinib (HKI-272)发表文献68篇：

Cancer Cell, 2021, S1535-6108(21)00284-1

PubMed: 34171264 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Genet, 2019, 51(2):207-216

PubMed: 30531871 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):224-37

PubMed: 23220880 ( click the link to review the publication )

Cancer Discov, 2012, 2(5):458-71

PubMed: 22588883 ( click the link to review the publication )

Cancer Med, 2021, 10(7):2370-2379

PubMed: 33665980 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 11(1):385

PubMed: 31959756 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO Mol Med, 2020, 8;12(5):e11498

PubMed: 32329582 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2838

PubMed: 33019652 ( click the link to review the publication )

Front Oncol, 2020, 10:554704

PubMed: 33330026 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

J Genet Genomics, 2020, 47(7):389-395

PubMed: 33004309 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(3):605-619

PubMed: 32036454 ( click the link to review the publication )

Pharmaceuticals (Basel), 2020, 14(1)E9

PubMed: 33374155 ( click the link to review the publication )

Cancer Sci, 2020, 111(3):849-856

PubMed: 31856375 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 31018595 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):135

PubMed: 31801615 ( click the link to review the publication )
Cell Commun Signal, 2019, 17(1):15

PubMed: 30786890 ( click the link to review the publication )

Cell Cycle, 2019, 18(13):1513-1522

PubMed: 31135266 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):2729-2736

PubMed: 30854046 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(4):807-820

PubMed: 28974546 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(6):1245-1258

PubMed: 29531020 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1865(8):1073-1087

PubMed: 29733883 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Front Chem, 2018, 6:47

PubMed: 29564326 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(17):5123-5134

PubMed: 28487443 ( click the link to review the publication )

Genome Med, 2017, 9(1):40

PubMed: 28446242 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29285221 ( click the link to review the publication )

Curr Protoc Chem Biol, 2017, 9(2):55-74

PubMed: 28628199 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(19):4859-4869

PubMed: 27697991 ( click the link to review the publication )

Cancer Lett, 2016, 382(2):176-185

PubMed: 27597738 ( click the link to review the publication )
Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Oral Dis, 2016, 22(8):797-804

PubMed: 27476950 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5305-13

PubMed: 26206867 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015,

PubMed: 26508629 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26375550 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1096-104

PubMed: 25081321 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Breast Cancer Res, 2013,

PubMed: 24044505 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Genetic Syndromes & Gene Therapy, 2013, 4:6

PubMed: ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(6):M112.017764

PubMed: 22345495 ( click the link to review the publication )

产品安全说明书

HER2抑制剂选择性比较

生物活性

产品描述

靶点

HER2 ^[1] (Cell-free assay)	EGFR ^[1] (Cell-free assay)	KDR ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)
59 nM	92 nM	800 nM	1.4 μM

体外研究

Neratinib微弱抑制酪氨酸激酶KDR 和Src，IC50分别为0.8 μM 和 1.4 μM,与 HER-2相比，活性分别弱14和24倍。Neratinib 作用于其他丝-苏氨酸激酶如Akt, cyclin D1/cdk4, cyclin E/cdk2, cyclin B1/cdk1, IKK-2, MK-2, PDK1, c-Raf, 和Tpl-2，以及酪氨酸激酶c-Met没有活性。Neratinib选择性抑制转染 HER-2 (3T3/neu)的3T3细胞增殖,也抑制两种其他 HER-2-过表达的SK-Br-3和 BT474 cells细胞增殖，IC50为 2-3 nM,与未转染的3T3细胞及 EGFR-和 HER-2阴性的MDA-MB-435 和 SW620细胞相比，效果高230倍以上。Neratinib也抑制EGFR-依赖的A431细胞增殖，IC50为81 nM。Neratinib 作用于BT474 细胞，降低HER-2受体自磷酸化， IC50 为5 nM,作用于A431细胞，降低EGF依赖的 EGFR磷酸化，IC50 为3 nM。Neratinib抑制 HER-2，导致下游MAPK和Akt通路受抑制，IC50为2 nM,比Trastuzumab更有效。Neratinib 作用于BT474细胞，抑制cyclin D1表达和 Rb-敏感性基因产物的磷酸化，IC50为9 nM,导致细胞周期停在G1-S期，最终降低细胞增殖。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
BT-474	NUnOTpBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3qwZmlEPTB:MD6wNFUh\|ryP	NX7Jb5FZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
EFM-192A	NXyzXIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnvJTWM2ODxyLkCwOUDPxE1?	M2XueVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
HCC1569	M4[4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFu4O4FKSzVyPECuNFA2KM7:TR?=	NHLxd2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwPVA3PCd-MkSwNFkxPjR:L3G+
HCC1954	NYLpVmh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUPJR\|UxRDBwMEC1JO69VQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDByOUC2OEc,OjRyMEmwOlQ9N2F-
MDA-MB-175	NV;KW2VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn[0TWM2ODxyLkCwOUDPxE1?	M4fPTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
MDA-MB-361	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXeydlk3UUN3MEywMlAxPSEQvF2=	NFj1W\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwPVA3PCd-MkSwNFkxPjR:L3G+
SK-BR-3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVLCU45KUUN3MEywMlAxPSEQvF2=	M1v6SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
UACC-812	NHLBRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFvwWYtKSzVyPECuNFA2KM7:TR?=	M4m1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
UACC-893	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFLnSJdKSzVyPECuNFA2KM7:TR?=	NWPRc2I4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
SUM-225	NHnybItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1fWfGlEPTB;MD6wNUDPxE1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDByOUC2OEc,OjRyMEmwOlQ9N2F-
SUM-190	NHP1c2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mm\kTWM2OD1yLkCxJO69VQ>?	NVj6OmlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
ZR-75-1	M{TtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVHJR\|UxRTBwMEOg{txO	NWjrO\|Q3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
HCC70	MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXfJR\|UxRTBwMEOg{txO	M13EflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
BT-20	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnvsTWM2OD1yLkC3JO69VQ>?	Mn7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMEmwOlQoRjJ2MEC5NFY1RC:jPh?=
MDA-MB-453	NUiwWFh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGjnToJKSzVyPUCuNFkh\|ryP	M{HT[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
HCC1187	M1i4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWm5WFF5UUN3ME2wMlExKM7:TR?=	MoDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMEmwOlQoRjJ2MEC5NFY1RC:jPh?=
EFM-19	NX\BPXdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3;lZmlEPTB;MD6xNUDPxE1?	M2DtclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
T-47D	NVvEZY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGKwN3JKSzVyPUCuNVYh\|ryP	NVvrSIt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
MDA-MB-134	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFrPZmhKSzVyPUCuNVch\|ryP	NUC1[INRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
HCC38	NXW0cIU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWDJR\|UxRTBwMkWg{txO	M2XiTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
MDA-MB-435	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3i0[2lEPTB;MD6zN{DPxE1?	NWThbnhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
MDA-MB-468	MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnLTTWM2OD1yLkOzJO69VQ>?	MnvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMEmwOlQoRjJ2MEC5NFY1RC:jPh?=
CAMA-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV;JR\|UxRTBwM{eg{txO	NFXmUI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwPVA3PCd-MkSwNFkxPjR:L3G+
MDA-MB-436	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVjDN5NjUUN3ME2wMlQyKM7:TR?=	NF62O2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwPVA3PCd-MkSwNFkxPjR:L3G+
MCF-7	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVfFPZF{UUN3ME2wMlQyKM7:TR?=	NV\YVXZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
MDA-MB-415	NHn6NYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH64bmtKSzVyPUCuOFIh\|ryP	MljkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMEmwOlQoRjJ2MEC5NFY1RC:jPh?=
HCC1806	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkD2TWM2OD1yLkS0JO69VQ>?	M3m0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
HCC1395	MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVzJR\|UxRTBwNEmg{txO	NXy2PI5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkxPjRpPkK0NFA6ODZ2PD;hQi=>
HCC1937	NXLQW4tqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWfJR\|UxRTBwNUCg{txO	NHPXR289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwPVA3PCd-MkSwNFkxPjR:L3G+
HCC1143	M4\sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFTYOXNKSzVyPUCuOVQh\|ryP	MojOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMEmwOlQoRjJ2MEC5NFY1RC:jPh?=
UACC-732	M{f5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MknvTWM2OD1yLk[1JO69VQ>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDByOUC2OEc,OjRyMEmwOlQ9N2F-
MDA-MB-231	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3z5d2lEPTB;MT6wNEDPxE1?	M1\ublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
MDA-MB-157	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1\0cGlEPTB;MT6xNkDPxE1?	M{ez[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
BT-549	NVHqSHo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWW1R2MzUUN3ME2xMlE1KM7:TR?=	NHTRRpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwPVA3PCd-MkSwNFkxPjR:L3G+
KPL-1	M3jreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4DoWmlEPTB;MT64PUDPxE1?	MoLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMEmwOlQoRjJ2MEC5NFY1RC:jPh?=
CAL-51	NX7a[m5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXXvZXFQUUN3ME2xMlg6KM7:TR?=	M2O1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NFY1Lz5{NECwPVA3PDxxYU6=
BT474	NH7jO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX3JR\|UxRTBwMECzNlMhyrFiMD6wNFA4PSEQvF2=	NELmeGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ixOlI2PCd-MkO4NVYzPTR:L3G+
SKBR3	M1PUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIO5OlBKSzVyPUCuNFA4PSEEsTCwMlAxPSEQvF2=	NYjMVZdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVYzPTRpPkKzPFE3OjV2PD;hQi=>
MDAMB453	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkfVTWM2OD1zLkW5JOKyKDBwMUe5JO69VQ>?	NVLtV3ZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVYzPTRpPkKzPFE3OjV2PD;hQi=>
KB	NFmyZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV3WPVNuUUN3ME20MlE{KMLzIECuOFch\|ryP	NFPrS449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5NVk{PSd-MkK0PVE6OzV:L3G+
KBv200	M1;yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIHqem1KSzVyPU[uNFMhyrFiMD62OEDPxE1?	NYf3WVNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVE6OzVpPkKyOFkyQTN3PD;hQi=>
MCF-7	NIH0[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXvpbmpHUUN3ME2zMlMxKMLzIECuOFEh\|ryP	NI\Ofog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5NVk{PSd-MkK0PVE6OzV:L3G+
MCF-7/Adr	NIDTfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXvJR\|UxRSB{Lki4JOKyKDBwM{Cg{txO	Ml7EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUG5N\|UoRjJ{NEmxPVM2RC:jPh?=
MCF-7	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIXQc4lKSzVyPUOuNFIhyrFiMD6zOEDPxE1?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR7MUmzOUc,OjJ2OUG5N\|U9N2F-
MCF-7/FLV1000	Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MknWTWM2OD15LkC5JOKyKDBwN{Gg{txO	NGnwVpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5NVk{PSd-MkK0PVE6OzV:L3G+
HL60	NH64eY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYDvWI1tUUN3ME2yMlI3KMLzIECuNlMh\|ryP	NEPMUIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5NVk{PSd-MkK0PVE6OzV:L3G+
HL60/Adr	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHXoZ4xKSzVyPUGuOFIhyrFiMD6xOUDPxE1?	MoHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUG5N\|UoRjJ{NEmxPVM2RC:jPh?=
HEK293/pcDNA3.1	M2riXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV;JR\|UxRTVwMkmgxtEhOC53MzFOwG0>	MnLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUG5N\|UoRjJ{NEmxPVM2RC:jPh?=
HEK293/ABCB1	NHnOZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmfuTWM2OD14LkmxJOKyKDBwN{CgJO69VQ>?	M4LYOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEmxPVM2Lz5{MkS5NVk{PTxxYU6=
SKBR	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MViwMlAyNTFyMDDuUS=>	Mn;hN{04KGR?	Ml7CbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR6N{[wOUc,OjF2OEe2NFU9N2F-
L858R(EGFR)	MmHCR4VtdCCYaXHibYxqfHliQYPzZZk>			MoHv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M{\DSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{GxNFAzLz5zN{OxNVAxOjxxYU6=
L858R/T790M(EGFR)	MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>			M1\WOIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNzMUCwNkc,OTd\|MUGwNFI9N2F-
G776insV_G/C	MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>			NVXIdng2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNzMUCwNkc,OTd\|MUGwNFI9N2F-
wild-type	MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>			Ml;n[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NGS2Vnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OxNVAxOid-MUezNVExODJ:L3G+
A775insYVMA	NGTm[Y5E\WyuIG\pZYJqdGm2eTDBd5NigQ>?			NULhUYNz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNzMUCwNkc,OTd\|MUGwNFI9N2F-
G776insV_G/L	MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>			NEewOGFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4hfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NHPmVGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OxNVAxOid-MUezNVExODJ:L3G+
P780insGSP	M2Pp[mNmdGxiVnnhZoltcXS7IFHzd4F6			NU\oRmJM\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NXq5dHVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezNVExODJpPkG3N\|EyODB{PD;hQi=>
NCI-H1781	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2HuUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MnzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6MUi2NVgoRjF4OEG4OlE5RC:jPh?=
HCC827	NUTLVZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2rDU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M{G0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEG4OlE5Lz5zNkixPFYyQDxxYU6=
H3255	MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXq2cIxDcW6qaXLpeJMh[2WubDDndo94fGhiaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVz	NVrtb2NzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4NVg3OThpPkG2PFE5PjF6PD;hQi=>
NCI-H1975	NHzuNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mnf5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NVzlNIV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4NVg3OThpPkG2PFE5PjF6PD;hQi=>
A549	MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGC1eolqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NEXWS3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkixPFYyQCd-MU[4NVg3OTh:L3G+
3T3	Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4LiT2lEPTB;N{CwJOKyKDd6IH7N	NULsV4syRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxO\|MxODhpPkG1NVc{ODB6PD;hQi=>
3T3/neu	NHLlSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4fsVGlEPTB;MzFCtUAxNjF2IH7N	NVHzTIdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxO\|MxODhpPkG1NVc{ODB6PD;hQi=>
SK-Br-3	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUTJR\|UxRTJiwsGgNE4yQCCwTR?=	M3q0[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUezNFA5Lz5zNUG3N\|AxQDxxYU6=
BT 474	NXj1[ZRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4P1O2lEPTB;MjFCtUAxNjB4IH7N	NFfvS2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG3N\|AxQCd-MUWxO\|MxODh:L3G+
A431	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NInPXpNKSzVyPUixJOKyKDlibl2=	NEjjWpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG3N\|AxQCd-MUWxO\|MxODh:L3G+
MDA-MB-435	NXrySnZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHjUUI1KSzVyPUm2NEDDuSBzNkWgcm0>	MkTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzN{OwNFgoRjF3MUezNFA5RC:jPh?=
SW620	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mne1TWM2OD14OUCgxtEhQDRibl2=	MlPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzN{OwNFgoRjF3MUezNFA5RC:jPh?=
SKBR3	MoLPSpVv[3Srb36gZZN{[Xl?			NXLFbY5vUW6qaXLpeIlwdiCxZjDoeY1idiCKZYKyJIlvKFONQmKzJINmdGy\|LDDFR\|UxKD1iMD6wNFIh\|ryPLh?=	Mo\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyN{e0NlUoRjF6MEe3OFI2RC:jPh?=
BT474	NWO5SplqTnWwY4Tpc44h[XO\|YYm=			MYjJcohq[mm2aX;uJI9nKGi3bXHuJGhmejJiaX6gRnQ1PzRiY3XscJMtKEWFNUCgQUAxNjByMjFOwG0v	M13XXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEe3OFI2Lz5zOEC3O\|QzPTxxYU6=
A431	Mm\lSpVv[3Srb36gZZN{[Xl?			M3PNeGlvcGmkaYTpc44hd2ZiaIXtZY4hUGW{MjDpckBCPDNzIHPlcIx{NCCHQ{WwJF0hOC5yOEGg{txONg>?	MlnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyN{e0NlUoRjF6MEe3OFI2RC:jPh?=
SW620	MkW1SpVv[3Srb36gZZN{[Xl?			MnvkTY5pcWKrdHnvckBw\iCqdX3hckBJ\XJ{IHnuJHNYPjJyIHPlcIx{NCCHQ{WwJF0hOC54OTFOwG0v	NGjPb3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O\|QzPSd-MUiwO\|c1OjV:L3G+
BA/F3	MoPOR5l1d3SxeHnjbZR6KGG\|c3H5			M{DHTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6UjDteZRidnRuIFnDOVAhRSByLkCwN\|Uh\|ryPLh?=	NXHnVIJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN\|kzOjlpPkG5NlM6OjJ7PD;hQi=>
BA/F3	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=			NWHGS41yS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfCxiSVO1NEA:KDBwMUig{txONg>?	M2LhWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkO5NlI6Lz5zOUKzPVIzQTxxYU6=
Sf9	NXfOUJVoTnWwY4Tpc44h[XO\|YYm=		NIPJRWUyOCCvaX7z	MWDJcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGT0[UIHX4dJJme3OnZDDpckBU\jliY3XscJMhfXOrbnegX4didW2jM{LQYU1CXFBiYX\0[ZIhOTBibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBKSzVyIE2gNE4xODJ3IN88UU4>	MnmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2OFMoRjJ2OUCwOlQ{RC:jPh?=
Sf9	NWnHV29{TnWwY4Tpc44h[XO\|YYm=		NX\BWIl7OTBibXnudy=>	M3XVR2lvcGmkaYTpc44hd2ZiaIXtZY4hTUeIUjDUO\|kxVS:OOEW4VkBufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyC3c3nu[{Bc\2GvbXGzNnBeNUGWUDDh[pRmeiBzMDDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjB4NjFOwG0v	Ml3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2OFMoRjJ2OUCwOlQ{RC:jPh?=
BAF3	MV7GeY5kfGmxbjDhd5NigQ>?		MY[3NkBpenN?	NEfvWI9KdmirYnn0bY9vKG:oIGTlcE1nfXOnZDDJS2YyWiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4yQSEQvF2u	NXrPbXE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	M1e3fGZ2dmO2aX;uJIF{e2G7		MnTIO\|IhcHK\|	NFnRNWRKdmirYnn0bY9vKG:oIGTlcE1nfXOnZDDJUnNTKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlI6KM7:TT6=	Mln3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3	MkS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUe0ZXJ3PzJiaILz	MlXjS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgRmFHOyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFEvQSEQvF2u	NITtb4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pHER2 / HER2 / pAKT / AKT / pERK / ERK ; PubMed: 24009064 Oncotarget BT474 (right) and SKBR3 (left) cell were treated for 1 hour or 1 day with increasing concentrations of neratinib. After lysis, protein levels were assessed using western blotting techniques. p-ERBB2 / ERBB2 / p-ERBB3 / ERBB3 / p-EGFR / p-90RSK ; PubMed: 30118499 PLoS One (A) Effects of MEK162 alone, neratinib alone, and the combination of MEK162 plus neratinib were assessed in sensitive, inflammatory subtype cell lines (NCI-H747, SW-837), (B) resistant, stem-like subtype cell lines (SW480, SW620). Cell lines were cultured䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣痖뙠ෆ𢡄뙤ෆ䀷痗뙤ෆ౴뙤ෆ㵶痗뙤ෆ뺖᎒泌Itemｾ᎒	24009064 30118499
Growth inhibition assay	Cell viability ; PubMed: 30118499 PLoS One NCI-H747, SW837, SW1116, SW1463, NCI-H508, SNU-C1, SW480, SW620, C2BBE1, Hs675.T, and HCT116 cells were treated with a constant dose of MEK162 (0.5 μM) in combination with different doses of neratinib for 72 hours. Dimethyl sulfoxide (DMSO) (0.01%) was us䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒	30118499

体内研究

Neratinib每天按10, 20, 40, 和80 mg/kg剂量口服处理给药3T3/neu 移植瘤，显著抑制生长，分别抑制34%, 53%, 98%, 和 98%。Neratinib每天按40 mg/kg剂量处理，1小时内抑制 84% HER-2磷酸化，相应地，Neratinib 每天按5, 10, 和 40 mg/kg剂量处理BT474 移植瘤，抑制分别为70-82%, 67%, 和 93%。Neratinib也有效作用于SK-OV-3移植瘤，每天按 5 和 60 mg/kg剂量处理，抑制分别为 31% 和85% 。Neratinib作用于EGFR依赖性A431移植瘤比作用于HER-2-依赖性肿瘤效果弱, 每天按5 和 20 mg/kg剂量处理，抑制分别为32%和44%。Neratinib作用于表达低水平HER-2和EGFR的MCF-7和 MX-1移植瘤几乎没有活性, 每天按80 mg/kg剂量处理抑制只为28%，说明Neratinib 选择性作用于表达HER-2或EGFR的细胞。^[1]

激酶实验：^[1]	- 合并使用时间-分辨荧光分析无细胞自磷酸化: Neratinib 在DMSO 中制备成10 mg/mL 储液，然后在25 mM HEPES (pH 7.5; 0.002 ng/mL-20 μg/mL)中稀释。纯化重组的HER-2 COOH末端片段(第676-1255位氨基酸) 或EGFR COOH末端片段(第 645-1186位氨基酸)[在100 mM HEPES (pH 7.5) 和50% 甘油中稀释] 与浓度不断增高的Neratinib 在96-孔ELISA板上室温下温育15分钟，孔中含4 mM HEPES (pH 7.5), 0.4 mM MnCl₂, 20 μM 钒酸钠，及 0.2 mM DTT 。加入 40 μM ATP 和20 mM MgCl₂开始激酶反应，然后在室温下反应1小时。冲洗实验板, 使用铕标记的抗-磷酸化-酪氨酸抗体 (15 ng/每孔)检测磷酸化。冲洗后，使用Victor2 荧光读数仪 (激发波长为340 nm,发射波长为615 nm)测定信号。通过抑制曲线测定抑50%受体磷酸时的Neratinib 浓度 (IC50) 。
细胞实验：^[1]	- 合并 Cell lines: 3T3, 3T3/neu, A431, BT474, SK-Br-3, MDA-MB-435, 和SW480 Concentrations: 溶于DMSO, 终浓度为0.5 ng/mL-5 μg/mL Incubation Time: 2, 或6天 Method: 使用不同浓度Neratinib处理细胞 2, 或6 天。使用sulforhodamine B, 一种蛋白结合染料，测定细胞增殖。细胞与10% 三氯乙酸混合，然后使用水广泛冲洗。使用 0.1% sulforhodamine B对细胞进行染色，使用在5% 乙酸中清洗。蛋白-结合染10 mM Tris中,然后在450 nM处测定吸光度。通过抑制曲线测定抑制50% 细胞增殖时的Neratinib 浓度(IC50)。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 皮下移植3T3/neu, BT474, MCF-7, 或 SK-OV-3 细胞的雌性无胸腺裸鼠 Dosages: ~80 mg/kg/day Administration: 口服饲喂 (Only for Reference)

参考文献

[1] Rabindran SK, et al. Cancer Res, 2004, 64(11), 3958-3965.

溶解度 (25°C)

体外	DMSO	5 mg/mL warmed (8.97 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% propylene glycol	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Neratinib (HKI-272) SDF

分子量	557.04
化学式	C₃₀H₂₉ClN₆O₃
CAS号	698387-09-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04781374	Not yet recruiting	Drug: Neratinib	Metastatic Prostate Adenocarcinoma\|Castration-resistant Prostate Cancer\|Prostate Cancer\|Prostate Cancer Metastatic	Dana-Farber Cancer Institute\|Puma Biotechnology Inc.	August 2021	Phase 2
NCT03919292	Recruiting	Drug: Neratinib\|Drug: Divalproex Sodium	Solid Tumor Adult	Virginia Commonwealth University\|Puma Biotechnology Inc.	May 1 2019	Phase 1\|Phase 2
NCT01128842	Completed	Drug: Neratinib\|Drug: Capecitabine	Advanced Malignant Solid Tumors	Puma Biotechnology Inc.	April 2010	Phase 1
NCT00878709	Completed	Drug: neratinib\|Other: placebo	Breast Cancer	Puma Biotechnology Inc.	July 9 2009	Phase 3
NCT00814060	Completed	Drug: neratinib	Healthy Subjects	Puma Biotechnology Inc.	January 2009	Phase 1
NCT00741260	Completed	Drug: Neratinib\|Drug: Capecitabine	Breast Cancer	Puma Biotechnology Inc.	December 9 2008	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

HER2 Signaling Pathway Map

HER2 Inhibitors with Unique Features

选择性强的HER2抑制剂

CP-724714 : HER2/ErbB2-selective, IC50=10 nM.
活性最高的HER2抑制剂

Mubritinib (TAK 165) : HER2/ErbB2, IC50=6 nM.
FDA批准的HER2抑制剂

Lapatinib : Approved by FDA for breast cancer.
经典的HER2抑制剂

Lapatinib (GW-572016) Ditosylate : Dual EGFR/ErbB2 inhibitor, IC50=10.8/9.2 nM.

研究领域

产品类型

定制您的化合物库

Neratinib (HKI-272)

客户使用Selleck生产的Neratinib (HKI-272)发表文献68篇：

产品安全说明书

HER2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Neratinib (HKI-272) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

HER2 Signaling Pathway Map

HER2 Inhibitors with Unique Features

相关HER2产品